Julie Estève

Julie Estève has had a diverse work experience. Julie started their career as a Research Trainee at Pôle Biologie Santé in 2012, where they developed functional testing tools for the CHD7 protein. In 2013, they worked as a Research Trainee at BMGIC - U1035 (Inserm - Université de Bordeaux), conducting a study on the effects of proteasome inhibition in the treatment of congenital erythropoietic porphyria. That same year, they also worked as a Pharmacy Technician at Pharmacie Joubert.

In 2014, Julie worked as a Pharmacy Trainee at CHU de Poitiers, where they developed an internal control network for implantable medical devices and created communication media for promoting good medicine usage.

From 2015 to 2018, Julie pursued their PhD in Genetics at BMGIC - U1035 (Inserm - Université de Bordeaux), specializing in a genetic research project. Following their PhD, they returned to BMGIC as a Research Trainee in 2015, focusing on genetics.

In 2019, Julie joined IXEO-Conseil as an Innovation Consultant, assisting in the development and financing of innovative companies. Julie provided advice on organizational and social models and supported companies in obtaining research and innovation tax credits. Additionally, they helped companies prepare applications for funding programs such as the European EIC Accelerator and the i-Lab and i-Nov contests.

Julie's most recent position is as a Business Developer at Synapse Medicine, starting in April 2022. Additional information about this role is not provided.

Julie Estève has a diverse education history. Julie started by completing their Baccalauréat Scientifique with an emphasis in SVT (biology) at Lycée de l'Image et du Son d'Angoulême in 2009. Julie then went on to attend Université de Poitiers and earned a Master 1 degree in "Biologie Santé Sciences du Médicament_Recherche et Ingénierie en Biosanté" from 2011 to 2013. In 2014, Julie enrolled at Paris-Sud University (Paris XI) and obtained a Master 2 degree in "Biotechnologie pharmaceutique et thérapies innovantes" with a focus on biotechnology and biotherapies. Julie continued their education at Université de Poitiers and earned a PharmD degree, but the specific field of study is not mentioned. Julie also attended various conferences and events related to their field, including the 25th Anniversary Congress of the European Society of Gene and Cell Therapy in 2017, INGESTEM Congress 2015 on Infrastructure nationale d'ingénierie des cellules souches pluripotentes, and Brain Education event on the industry perspectives for young researchers within the pharmaceutical sector. Julie's education also included a short program at Ecole de l'Innovation Thérapeutique in 2018, which involved collaborations with organizations such as ARIIS, AVIESAN, Labex LERMIT, LEEM, OPCA DEFI, and Inserm.